Emmecell

?? Game-Changing Progress in Corneal Edema Treatment: Emmecell's EO2002 Emmecell has announced promising results from its Phase 1 trial of EO2002, a groundbreaking non-surgical cell therapy for corneal edema. “EO2002 could transform how we treat corneal edema, significantly expanding access and improving outcomes for patients worldwide,” said Ellen Koo, MD, Bascom Palmer Eye Institute. ?? Learn more about how EO2002 is reshaping corneal edema treatment here: https://lnkd.in/d_rumJMy #EyeHealth #ClinicalTrial #Innovation #Treatment

We’re thrilled to announce that Emmecell has achieved positive topline results from a randomized, double-masked clinical trial for our groundbreaking non-surgical cell therapy for corneal edema. EO2002 is a first-in-class, non-surgical cell therapy designed for the ~ 90% of patients with symptomatic corneal edema who do not have a disease severe enough to warrant the risks of corneal transplantation surgery. A heartfelt thank you to our team, trial participants, and collaborators who have made this milestone possible. For more information, please visit www.emmecell.com

Congratulations, Ellen Koo, MD, on your work on guttae remodeling without surgery! This was a highlight of Cornea Subspecialty Day at #AAO2024 -Cornea Society https://lnkd.in/gdP_WCbS #MagneticCellDelivery #Fuchs #CornealEdema #CorneaSociety

Thank you to American Academy of Ophthalmology and Drs. Seitzman and Prescott for discussing #EO2002 and Emmecell’s #MagneticCellDelivery as one of the three highlights from Cornea Subspecialty Day at #AAO2024, referencing a great lecture delivered by Ellen Koo, MD on cell therapy for #CornealEdema, including a few cases of #guttata remodeling. (Discussion starts at 4:55 mark) https://lnkd.in/gCY_uZTw

See you at Eyecelerator @AAO! Dr. Jeffrey Goldberg will present exciting company updates. Throughout the conference, don't miss the opportunity to learn more about our magnetic cell delivery platform technology in several featured talks. #Eyecelerator #AAO2024 #EBAA

We are thrilled to announce that the final participant in our clinical trial for EO2002 (magnetic human corneal endothelial cells) has completed their last visit. EO2002 is a first-in-class, non-surgical cell therapy designed for the ~ 90% of patients with symptomatic corneal edema who do not have a disease severe enough to warrant the risks of corneal transplantation surgery. Congratulations to the wonderful team that made this possible! For more information, please visit www.emmecell.com

Join our team at Octane's Ophthalmology Tech Forum, to be held at VEA Newport Beach on June 20-21! We are honored to participate in the panel discussion titled “Innovations and Applications in Genetic Engineering and Cell Transplantation." We?look forward to connecting with peers and colleagues at the Forum, where we can explore new paths for collaboration ? Secure your spot today:?https://lnkd.in/eBF_MCr8? ? #OTF2024?#OphthalmicInnovation?#OphthalmicTech

Excited to announce a partnership with Eversight to advance our cell therapy programs https://lnkd.in/gczSAuhf